Emmaus Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

REVENUES, NET (Tables)

REVENUES, NET (Tables)

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Revenues, net by category were as follows (in thousands):


	Years ended December 31,
	2023		2022
Endari®	$	28,961	$	17,854
Other		636		536
Revenues, net		29,597		18,390

Revenue Allowance and Accrual Activities

The following table summarizes the revenue allowance and accrual activities for the years ended December 31, 2023, and 2022 (in thousands):


	Trade Discounts, Allowances and Chargebacks			Government Rebates and Other Incentives			Returns			Total
Balance as of December 31, 2021	$	1,481		$	3,133		$	539			5,153
Provision related to sales in the current year		2,672			2,857			1,416			6,945
Adjustments related to prior period sales		(56	)		18			537			499
Credit and payments made		(2,739	)		(2,290	)		(2,077	)		(7,106	)
Balance as of December 31, 2022		1,358			3,718			415			5,491
Provision related to sales in the current year		2,402			4,790			1,027			8,219
Adjustments related to prior period sales		(176	)		135			73			32
Credit and payments made		(2,372	)		(2,985	)		(652	)		(6,009	)
Balance as of December 31, 2023	$	1,212		$	5,658		$	863		$	7,733

Summarizes revenue attributable to each of the customers that accounted for 10% or more of net revenues

The following table summarizes revenue attributable to each of the customers that accounted for 10% or more of net revenues in either of the period shown:


	Years Ended December 31,
	2023			2022
Customer A		21	%		25	%
Customer B		22	%		27	%
Customer C		11	%		14	%
Customer D		14	%		13	%
Customer E		10	%		3	%
Total		78	%		82	%